Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Current Assets (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Current Assets data on record, last reported at $782.1 million in Q4 2025.

  • For Q4 2025, Current Assets rose 77.36% year-over-year to $782.1 million; the TTM value through Dec 2025 reached $782.1 million, up 77.36%, while the annual FY2025 figure was $782.1 million, 77.36% up from the prior year.
  • Current Assets reached $782.1 million in Q4 2025 per OCUL's latest filing, up from $387.0 million in the prior quarter.
  • Across five years, Current Assets topped out at $782.1 million in Q4 2025 and bottomed at $100.7 million in Q2 2023.
  • Average Current Assets over 5 years is $297.7 million, with a median of $222.3 million recorded in 2021.
  • Peak YoY movement for Current Assets: plummeted 38.64% in 2023, then skyrocketed 395.06% in 2024.
  • A 5-year view of Current Assets shows it stood at $191.3 million in 2021, then crashed by 32.24% to $129.6 million in 2022, then surged by 79.16% to $232.2 million in 2023, then soared by 89.89% to $441.0 million in 2024, then surged by 77.36% to $782.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $782.1 million in Q4 2025, $387.0 million in Q3 2025, and $433.4 million in Q2 2025.